International Extranodal NK/T-cell Lymphoma Project

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

770 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to explore risk factors for poor progression-free survival (PFS) and overall survival (OS) in ENKTL, and establish a prognostic model for ENKTL patients treated with non-anthracycline based treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

NCT03493451

Peripheral T Cell Lymphoma PTCL Extranodal NK/T-cell Lymphoma +16 more

COMPLETED PHASE2

Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma

NCT01341119

Extranodal NK/T Cell Lymphoma

COMPLETED

A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type

NCT02927925

Lymphoma

COMPLETED PHASE2

A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma

NCT01802138

Neuroblastoma

COMPLETED NA

Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study

NCT02691351

Non-Hodgkin T-cell Lymphoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a retrospective cohort study using anonymized information from patients with ENKTL. The following criteria are required: (1) Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2014; (2) Patients treated with non-anthracycline based therapy as an initial treatment. The pathology of initial diagnosis was reviewed by designated pathologists.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Extranodal NK/T-cell Lymphoma, Nasal Type

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Training cohort

1. Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2013;
2. Patients treated with non-anthracycline based therapy as an initial treatment.

No interventions assigned to this group

Validation cohort

1. Patients diagnosed with ENKTL, nasal type between January 1, 1998 and December 31, 2014;
2. Patients treated with non-anthracycline based therapy as an initial treatment.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with ENKTL, nasal type
* Patients diagnosed between January 1, 1995 and December 31, 2014
* Patients treated with nonanthracycline-based therapy as the initial treatment after diagnosis
* Nonanthracycline-based therapy includes the following treatments:
* Radiotherapy including concurrent chemoradiation

Exclusion Criteria

* Patients who had received anthracycline-based therapy, such as CHOP or CHOP-like regimens, as the initial treatment.
* Patients who do not have pathology slides available for central review.

Eligible Sex

ALL

Accepts Healthy Volunteers

No